Search research articles
Contact Us
Filters
Showing results (641-650 of 692) with videos related to
Page
of 70
Sort By:
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
Mirte Muller, Myron G Best, Vincent van der Noort, et al.
The Lancet. Oncology
|
February 3, 2022
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
Laurien J Zeverijn, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke A M G Pisters van Roy, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
H A Yu, C Baik, D-W Kim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Koichi Goto, Yasushi Goto, Toshio Kubo, et al.
Cell Reports. Medicine
|
November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Clinical Lung Cancer
|
May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
The Lancet Regional Health. Europe
|
March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
Karlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
Page
of 70
Search research articles
Search
Showing results (641-650 of 692) with videos related to
Sort By:
Page
of 70
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
Mirte Muller, Myron G Best, Vincent van der Noort, et al.
The Lancet. Oncology
|
February 3, 2022
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
Laurien J Zeverijn, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke A M G Pisters van Roy, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
H A Yu, C Baik, D-W Kim, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Koichi Goto, Yasushi Goto, Toshio Kubo, et al.
Cell Reports. Medicine
|
November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Clinical Lung Cancer
|
May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
The Lancet Regional Health. Europe
|
March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
Karlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
Page
of 70